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INTRODUCTION
Dermatomyositis (DM) is one of the idiopathic inflamma-
tory myopathies. It is clinically characterized by progressive
symmetrical proximal muscle weakness and a specific skin
manifestation. It has extramuscular manifestations such as
joint contractures, dysphagia, cardiac disturbance, pulmonary
symptoms, and subcutaneous calcifications. DM also has an
association with malignant disease, and various autoimmune
and connective tissue diseases. The average age at diagnosis
is 40 yr, and almost twice as many women are affected as men
(1). DM has bimodal onset age distribution. Most cases of
juvenile DM present between 5-14 yr of age and most adult
DM in the fifth and sixth decades of life (2). 
The incidence of juvenile DM is 2-3 cases per one million
per year (2-5), and adult DM is 5-10 cases per one million
per year (6). Major differences between juvenile and adult DM
include the greater potential for calcinosis, the presence of
vascular inflammation, and the potential for lipodystrophy
accompanied by insulin resistance in juvenile DM (7). DM
is still associated with morbidity and mortality rates as high
as 4-50%, principally related to life-threatening muscle weak-
ness and cardiac and lung complications. 
Although there have been many reports on DM, there is a
few study that compares juvenile to adult DM for clinical
characteristics and outcomes. The aim of this study is to clari-
fy the differences in clinical characteristics and outcomes bet-
ween juvenile and adult DM. 
MATERIALS AND METHODS
A total of 64 patients with juvenile DM (n=16) and adult
DM (n=48) were enrolled in this study. All patients were treat-
ed at Severance Hospital (Yongdong and Shinchon) or Konyang
University Hospital between January 1996 and December
2006. Diagnosis of DM in all cases was based on the criteria
defined by Bohan and Peter (8, 9): symmetric muscle weak-
ness, increased muscle enzymes, myopathic changes on elec-
tromyography, typical histological findings on muscle biop-
sy, and characteristic dermatologic signs. In this study, we
excluded patients with amyopathic dermatomyositis. 
We defined juvenile DM as onset of symptoms before 18
yr of age and adult DM as onset of symptoms after 18 yr of
age. We analyzed the following data from hospital records:
the age at diagnosis; current age; sex; duration of disease; dis-
tribution and degree of weakness; electrophysiological study
findings; presence of extramuscular manifestations such as
joint contractures, dysphagia, cardiac disturbance, pulmonary
symptoms, and subcutaneous calcifications; and associated
disorders such as mixed connective tissue disease, rheumatoid
arthritis, scleroderma, systemic lupus erythematosus, and
malignancy.
We analyzed the laboratory findings such as creatine kinase
(CK), alanine and aspartate aminotransferase (ALT, AST), an-
tinuclear antibodies (ANA), anti- Ro/SSA, anti-SSB/La, anti-
histidyl-tRNA synthesase (anti-Jo-1), anti-double-stranded
DNA, and rheumatoid factor (RF) at the time of presence of
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Clinical Characteristics and Outcomes of Juvenile and Adult 
Dermatomyositis
Dermatomyositis (DM) is an idiopathic inflammatory myopathy with bimodal onset
age distribution. The age of onset is between 5-18 yr in juvenile DM and 45-64 yr
in adult DM. DM has a distinct clinical manifestation characterized by proximal mus-
cle weakness, skin rash, extramuscular manifestations (joint contracture, dyspha-
gia, cardiac disturbances, pulmonary symptoms, subcutaneous calcifications), and
associated disorders (connective tissue disease, systemic autoimmune diseases,
malignancy). The pathogenesis of juvenile and adult DM is presumably similar but
there are important differences in some of the clinical manifestations, associated
disorders, and outcomes. In this study, we investigated the clinical characteristics
and outcomes of 16 patients with juvenile DM and 48 with adult DM. This study
recognizes distinctive characteristics of juvenile DM such as higher frequency of
neck muscle involvement, subcutaneous calcifications, and better outcomes.
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muscle weakness. 
Principles of treatment for both juvenile DM and adult DM
were as follows: initial treatment was started with predniso-
lone in a daily dose of 0.5-1 mg/kg. Dose reduction was usu-
ally initiated after 4-6 weeks of full-dose therapy depending
on the degree of clinical improvement and steroid side effects.
In general, the dose of prednisolone was reduced by 5 mg/day
per week, reaching a level of 25-35 mg/day by the end of the
second month with a subsequent slower rate of reduction or
conversion to an alternate-day regimen. Oral methotrexate
(7.5-15 mg/week) or azathioprine (2-3 mg/kg/day) was used
in combination with prednisolone from the start in certain
patients, namely those with very severe myositis and those
with a long interval before commencement of treatment. They
were also added as second-line therapy in patients who res-
ponded slowly to steroid therapy, developed prominent steroid
side effects, or suffered relapse with steroid therapy alone.
Patients were followed up on a regular basis and were exam-
ined at 1-3 month intervals in an outpatient setting. During
each visit, patients underwent detailed physical and neuro-
logical examinations. The minimal follow-up duration was
34 months. Patients who died before 34 months were includ-
ed in the study. 
Evaluation of outcomes was performed on all patients bet-
ween September and December 2006. The outcomes of juve-
nile and adult DM patients during the evaluation period were
defined as 1) remission: disappearance of skin manifestations,
normalization of muscle strength, normal function of major
organs, normalization of both serum muscle enzyme levels
and electromyographic abnormalities-all persisting after ther-
apy discontinuation; 2) improvement: improvement of mus-
cle strength and skin manifestations, functions of involved
major organs, and biochemical data with therapy; 3) deteri-
oration: worsening of muscle strength and skin manifesta-
tions, functions of involved major organs, and biochemical
findings despite therapy; and 4) death: death of patient despite
therapy during the follow-up period.
Statistical analysis was performed using SPSS version 11.0
(SPSS Inc. Chicago, IL, U.S.A.). For group comparisons involv-
ing binary data, we used chi-square test and Fisher’s exact
test. Cumulative survival rates were calculated, using Kaplan-
Meier method for the whole series. The significance of the
survival difference was examined by the log-rank test, and
P<0.05 was considered statistically significant. 
RESULTS
Clinical and laboratory characteristics of juvenile DM 
Details of each patient are given in Table 1. There were 16
patients (patient Nos. 1-16), 6 males and 10 females, who had
typical muscle pathology and electrophysiological findings
consistent with DM. Onset age varied from 4-12 yr. The mean
duration of disease was 52 months (range, 34-110 months).
Onset symptoms were skin rash in 6 patients and limb weak-
ness in 10. Most showed symmetrical proximal muscle weak-
ness, and none showed facial weakness. Eight out of 16 pati-
ents showed neck muscle weakness. Six patients showed dys-
phagia. Six patients showed right bundle branch block or
ST-T wave abnormality on electrocardiography (EKG). None
of the patients showed interstitial lung disease on chest radio-
graphy. Six patients showed subcutaneous calcifications. One
patient showed systemic lupus erythematosus, scleroderma,
and joint contracture. None of the patients showed mixed con-
nective tissue disease, rheumatoid arthritis, or malignancy. 
CK was increased in 12 patients. ALT was increased in 8
patients. AST was increased in 12 patients. ANA with a speck-
led pattern were present in 5/12 (41.7%) patients. Anti-Ro/
SSA antibodies and anti-ds DNA antibodies were detected
in 1/12 (8.3%) patients. Anti-La/SSB antibodies, anti-Jo-1
antibodies, RF were negative in all patients. 
Clinical and laboratory characteristics of adult DM
Details of each patient are given in Table 1. There were 48
patients (patient Nos.17-64), 17 males and 31 females, who
had typical muscle pathology and electrophysiological find-
ings consistent with DM. Onset age varied from 20-73 yr.
The mean duration of disease was 41 months (range, 3-110
months). Onset symptoms were skin rash in 31 patients and
limbs weakness in 17. Most patients showed symmetrical
proximal muscle weakness and few showed facial weakness.
Five out of 48 patients showed neck muscle weakness. Nine
patients showed dysphagia. Eleven out of 48 patients showed
right bundle branch block, ST-T wave abnormality, or tach-
yarrhythmia on EKG. Six patients showed interstitial lung
disease on chest radiography. Six patients showed nasopharyn-
geal cancer, ovarian cancer, thyroid cancer, or cervical cancer.
Five patients showed mixed connective tissue disease and three
patients showed scleroderma. Two patients showed systemic
lupus erythematosus and one patient showed subcutaneous
calcifications, joint contracture, and rheumatoid arthritis. 
CK was increased in 46 patients. ALT was increased in 36
patients. AST was increased in 40 patients. ANA with a speck-
led pattern were present in 17/36 (44.7%) patients. Anti-Ro/
SSA antibodies were detected in 9/36 (25.0%) patients. Anti-
Jo-1 antibodies were detected in 6/36 (16.7%) patients. Anti-
ds DNA antibodies were detected in 2/36 (5.6%) patients.
Anti-La/SSB antibodies and RF were detected in patient res-
pectively out of 36. 
Clinical and laboratory comparison between juvenile and
adult DM patients
The frequency of neck muscle weakness and subcutaneous
calcification in patients with juvenile DM was significantly
higher than that of patients with adult DM (P<0.05, Table
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Distribution of muscle weakness
Patient
No.
Sex/
Age
(yr)
Age 
of
onset
(yr)
Joint
con-
trac-
ture
Dys-
phagia
Car-
diac
distur-
bance
(EKG)
Subcu-
taneous
calci-
fication
Associ-
ated
disor-
ders
Malig-
nancy
Pulmonary
symptom
(Chest
radiogra-
phy)
Follow
up 
duration
(months)
Onset
Sx NeckFace
L/Ex
Prox DistalProx Distal
U/Ex
Juvenile DM
1 M/14 11 36 R 5 4+ 4+ 5 4+ 5 - - RBBB - + - -
2 F/10 5 58 L 5 5 4+ 5- 4 5- - + ND - - - -
3 F/11 7 40 A 5 4+ 4 5- 4 5- - - RBBB - - - -
4 M/14 10 39 U 5 5 4 5 4+ 5 - - ST - + - -
5 F/13 9 42 R 5 5 4+ 5 4+ 4+ - + NL - - - -
6 F/15 11 45 L 5 4+ 4+ 5- 4 5- - - NL - + - -
7 F/14 4 110 A 5 4 4+ 4+ 4 5- - - ND - - - -
8 F/14 11 36 R 5 5 4 5- 4+ 5- - - ST - - SLE -
9 F/13 10 35 L 5 4 4- 5- 4 4+ - + NL - - - -
10 F/15 12 34 A 5 4 3 4+ 3+ 4+ + + NL - + - -
11 M/11 7 38 R 5 5 4- 5- 4- 5- - - NL - - - -
12 F/10 6 42 R 5 5 4+ 5 4+ 5- - NL - - - -
13 M/13 9 45 U 5 5 4+ 5 5- 5 - ST - + - -
14 M/15 6 100 R 5 4+ 4+ 5 4 5- + NL - + SCL -
15 F/12 8 48 A 5 5 5- 5 4+ 5 - NL - - - -
16 M/16 9 80 L 5 4 4+ 5- 4+ 5- + RBBB - - - -
Adult DM
17 F/55 51 38 R 5 5 4+ 5- 4- 4+ - - ST - - - -
18 M/24 20 46 L 5 5 5 5 4- 4+ - - - - - - -
19 F/57 54 36 A 5 4+ 4- 5 4 5 - - - - - - -
20 F/62 59 36 L 5 5 4- 5 4 4+ + - RBBB ILD - SCL -
21 F/54 50 48 R 5 5 3+ 4+ 3+ 4+ - - - - - - -
22 M/59 55 40 U 5 5 4- 4+ 4- 4+ - + RBBB - - - -
23 F/56 52 42 R 5 5 4 4 3 4 - + - - - RA -
24 M/67 65 13 R 5 5 4 5 4- 5 - - - ILD - - -
25 M/57 56 11 R 5 5 4 4+ 4 4+ - - - - - - Naso Ca
26 M/53 43 110 R 5 5 5 5 5 5 - + ST - + MCTD -
27 F/45 41 40 R 5 3 4 5 4 5 - - - - - SCL -
28 F/69 69 6 A 5 5 3 5- 4- 5 - + - - - - Ovarian Ca
29 M/70 66 45 R 4 5 4 5 4+ 5 - - ST - - - -
30 F/46 45 3 L 5 5 4+ 5 4+ 5 - - - ILD - MCTD -
31 F/55 52 36 R 5 5 3 5 3 5 - + - - - - -
32 M/64 60 44 L 5 5 5 5 4+ 5 - - ST - - - -
33 F/34 30 42 R 5 5 4+ 5 5 5 - - - - - - -
34 F/47 42 60 R 5 5 5- 5- 5- 5- - - - - - - Cervical Ca
35 F/32 27 50 A 5 4+ 4 4+ 4 5 - - - - - - -
36 F/54 50 48 R 5 5 5- 5 5- 5 - - - - - - Thyroid Ca
37 F/50 46 38 L 5 5 5 5 4- 5- - - - - - - -
38 F/32 29 36 R 5 5 4+ 5- 4- 5- - - - - - - -
39 M/76 73 36 R 5 5 4 4+ 4 4+ - - - - - - -
40 M/37 37 5 A 5 3 3 4+ 4 4+ - - TA ILD - MCTD -
41 F/34 30 40 R 5 5 4- 5 4- 5- - - - - - - -
42 F/30 26 38 R 5 5 4- 4+ 4- 4+ - - - - - - -
43 M/56 52 42 R 5 5 4- 4+ 4- 4+ - + - - - - Naso Ca
44 F/24 20 44 A 5 4- 4- 5 4- 5 - - ST - - - -
45 F/25 21 40 L 5 5 3 4+ 4- 4+ - - - - - SLE -
46 M/24 21 36 R 5 4+ 4- 4+ 4- 4+ - - - - - - -
47 M/32 26 72 U 5 5 4+ 5 5 5 - - - - - - -
48 F/27 21 68 R 5 5 4 5- 4+ 5- - - - - - - -
49 M/28 24 47 A 4+ 5 4+ 5- 4+ 5- - - - - -
50 F/30 27 34 R 5 5 4+ 5 4- 5- - RBBB ILD - SLE -
51 F/37 31 70 L 5 5 5- 5 4+ 5 + - - - -
Table 1. Characteristics of juvenile and adult dermatomyositis (DM) patients 
(Continued next page)
2). Comparing the frequency of dysphagia, EKG abnormal-
ity, interstitial lung disease, joint contracture, overlap syn-
drome, and malignancy, there was no statistically significant
difference between juvenile and adult DM (Table 2).
Comparing the frequency of raised CK, raised ALT, raised
AST, positive ANA, positive anti-Ro/SSA, positive anti-La/
SSB, positive anti-Jo-1, positive anti-ds DNA, and positive
RF, there was no statistically significant difference between
juvenile and adult DM (Table 2).
The median follow-up duration of juvenile and adult DM
patients was 52 months (range, 34-110 months) and 41 mon-
ths (range, 3-110 months), and there was no statistically sig-
nificant difference between two groups. The outcomes of pa-
tients with juvenile and adult DM are summarized in Table
3. In the 16 patients with juvenile DM, 9 patients (56.2%)
had remission. Six patients (37.5%) had improvement of juve-
nile DM. The 1 remaining patient (6.3%) had a deteriorating
course. None of the 11 patients with juvenile DM died dur-
ing follow-up. Eighteen out of 48 adult DM patients (37.5%)
had remission and 17 (35.4%) had improvement. Three pa-
tients (6.3%) had deterioration of adult DM. Ten out of the
total 48 patients with adult DM died during the follow up.
The mortality rate of adult DM was 20.8% and significant-
ly higher than juvenile DM (0%) (P<0.001). The survival
difference between juvenile and adult DM by log-rank test
was statistically not significant (P=0.0544) (Fig. 1). 
The characteristics of patients with adult DM who died
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Juvenile DM
(n=16)
Adult DM
(n=48)
P value
Neck muscle weakness 8 (50%) 10 (20.8%) 0.03
Joint contracture 1 (6%) 1 (2.1%) NS
Dysphagia 6 (37.5%) 9 (18.8%) NS
EKG abnormality 6 (37.5%) 11 (22.9%) NS
Interstitial lung disease 0 6 (12.5%) NS
Subcutaneous calcification 6 (37.5%) 1 (2.1%) 0.01
Overlap syndrome 2 (12.5%) 11 (22.9%) NS
Malignancy 0 6 (12.5%) NS
Raised CK 12 (75.0%) 46 (95.8%) NS
Raised ALT 8 (50.0%) 36 (78.3%) NS
Raised AST 12 (75.0%) 40 (87.0%) NS
Positive ANA 5 (41.7%)* 17 (44.7%)� NS
Positive anti-Ro/SSA 1 (8.3%)* 9 (25.0%)� NS
Positive anti-La/SSB 0* 1 (2.8%)� NS
Positive anti-Jo-1 0* 6 (16.7%)� NS
Positive anti-ds DNA 1 (8.3%)* 2 (5.6%)� NS
Positive RF 0* 1 (2.8%)� NS
Table 2. Comparison of clinical and laboratory characteristics
between juvenile and adult DM patients
*Data available for twelve patients; �data available for 36 patients.
DM, dermatomyositis; CK, creatine kinase; ALT, alanine aminotrans-
ferase; AST, aspartate aminotrnasferase; ANA, antinuclear antibodies;
Jo-1, histidyl-tRNA synthetase; RF, rheumatoid factor; ds DNA, double-
stranded DNA; NS, not significant.
Juvenile DM
(n=16)
Adult DM
(n=48)
P value
by Fisher’s
exact test
Remission 9 (56.2%) 18 (37.5%) NS
Improvement 6 (37.5%) 17 (35.4%) NS
Deterioration 1 (6.3%) 3 (6.3%) NS
Death 0 (0%) 10 (20.8%) <0.001
Table 3. Outcomes of juvenile and adult DM patients  
DM, dermatomyositis; NS, not significant.
R, rash; A, all limds weakness; U, upper limb weakness; L, lower limb weakness; ST, ST-T wave abnormality; RBBB, right bundle branch block; TA,
tachyarrythmia; NL, normal; ND, not done; ILD, interstitial lung disease; SCL, scleroderma; SLE, systemic lupus erythematosus; MCTD, mixed con-
nective tissue disease; Naso Ca, nasopharyngeal cancer; Ovarian Ca, ovarian cancer; Cervical Ca, cervical cancer; Thyroid Ca, thyroid cancer; Sx,
symptom; prox, moximal.
Distribution of muscle weakness
Patient
No.
Sex/
Age
(yr)
Age 
of
onset
(yr)
Joint
con-
trac-
ture
Dys-
phagia
Car-
diac
distur-
bance
(EKG)
Subcu-
taneous
calci-
fication
Associ-
ated
disor-
ders
Malig-
nancy
Pulmonary
symptom
(Chest
radiogra-
phy)
Follow
up 
duration
(months)
Onset
Sx NeckFace
L/Ex
Prox DistalProx Distal
U/Ex
52 M/39 33 65 A 5 4+ 4+ 5 5- 5- - - - - -
53 F/32 27 58 R 5 5 4+ 5 4+ 5 - - - MCTD -
54 F/33 29 47 L 5 5 5 5 4 4+ - - - - -
55 M/54 51 35 A 5 4+ 4+ 4+ 4+ 4+ + - - SCL -
56 F/45 42 36 U 5 5 4+ 5 5- 5 - - - - Ovarian Ca
57 F/35 31 45 U 5 5 4+ 5 5- 5 - TA - - -
58 F/32 28 46 R 5 5 5- 5 5- 5 - - - - -
59 M/58 57 5 U 5 5 4+ 5 5- 5 - - ILD - - -
60 M/40 37 36 A 5 4+ 4+ 5- 4+ 5- + - - - -
61 F/26 22 44 L 5 5 5- 5 4+ 5 - - - - -
62 F/38 35 36 R 5 5 4+ 5- 5- 5 - ST - MCTD -
63 F/40 36 47 L 5 5 5- 5 4+ 5 - - - - -
64 F/45 41 45 A 5 4+ 4+ 4+ 4+ 4+ - - - - - -
Table 1. (Continued from the previous page)  Characteristics of juvenile and adult dermatomyositis (DM) patients 
are shown in Table 4. Death was caused by cancer in 5 pati-
ents and by pulmonary complications in other 4 patients that
included pulmonary hypertension due to interstitial lung dis-
ease in 1 and aspiration pneumonia in 3. The 3 patients with
aspiration pneumonia concomitantly had moderate ventila-
tory insufficiency. One patient died from sepsis.
DISCUSSIONS
DM is characterized by subacute (over several weeks to
months), progressive, and proximal muscle weakness. In our
study, most patients with juvenile and adult DM had suba-
cute, progressive, and proximal muscle weakness. 
It is known that DM has a bimodal age distribution: one
peak occurs in children between 5-14 yr of age and a second,
larger peak occurs between 45-64 yr of age (10, 11). In our
study, onset age distribution was similar to that of previous
reports on juvenile DM (2, 12), but there was a wider varia-
tion of onset age distribution in adult DM. It is reported that
females outnumber males by 2: 1 (10, 11), and our study also
showed female predominance in both juvenile and adult DM. 
In our study, the difference of neck muscle weakness fre-
quency between juvenile and adult DM was statistically sig-
nificant (P=0.03). The reason of this result has been not ex-
plained until now and further study is needed. Neck flexors
muscle weakness is common in DM, but in some cases, there
is also severe weakness of neck extensor muscles. This has
been encountered particularly in patients with DM associat-
ed with scleroderma and mixed connective tissue disease (13).
In our study, neck flexor muscle weakness was present in 8
out of 16 patients with juvenile DM (50.0%) but neck exten-
sor muscle weakness was not. Neck flexor muscle weakness
was present in 10 out of 48 patients with adult DM (20.8%)
and in these cases, 3 patients with mixed connective tissue
disease or scleroderma also showed neck extensor muscle weak-
ness. 
Skin rash often precedes the onset of weakness by weeks
to months. Early in its course, rash and muscle enzyme ele-
vations may be the sole manifestations of DM (14). In our
study, most patients with juvenile and adult DM had proxi-
mal muscle weakness. The rash preceded muscle weakness in
6 out of 16 patients with juvenile DM (37.5%) and 23 out
of 48 patients with adult DM (47.9%). 
EKG abnormalities such as nonspecific ST-T wave change,
varying degrees of heart block and bundle branch block, and
tachyarrhythmia occur in up to 40% of DM patients (15).
In our study, EKG abnormalities were found in 6 out of 16
patients with juvenile DM (37.5%) and 11 out of 48 with
adult DM (22.9%). 
Calcinosis of the skin or muscle is unusual in adults, but
may occur in up to 40% of children or adolescents with DM
(16). In our study, subcutaneous calcifications were found in
6 out of 16 patients with juvenile DM (37.5%) and 1 out of
48 with adult DM (2.1%). The mechanism of calcinosis devel-
opment remains uncertain and there is still no standard treat-
ment for the condition. Juvenile DM with pathologic calci-
nosis is strongly associated with the tumor necrosis factor alpha
(TNF-α) 308 allele and increased production of TNF-α(17). 
Interstitial lung disease (ILD) is often associated with con-
siderable morbidity and mortality. The frequency of ILD in
DM varies, ranging from 5-47% in the different series and
tending to increase with the duration of the muscle disease;
the overall frequency is probably close to 9%. In our study,
ILD was found in 12.5% of adult DM patients and in none
of the juvenile DM patients. DM is an uncommon etiology
of ILD and most patients with ILD associated with DM pre-
sent between the ages of 20-40 yr (18). Therefore, we postu-
late that in the course of time, ILD may develop in juvenile
DM patients-the risk of ILD increasing with increased dura-
tion of DM.
The relationship of DM to malignancy has been recently
clarified (19). The reported frequency of malignancy in DM
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Sex/age
(yr)
Patient No.
Duration of 
disease (month)
Cause of death
20 F/62 36 Pulmonary 
hypertension/ILD
24 F/67 13 Sepsis
25 M/57 11 Cancer
28 F/69 6 Cancer
30 F/46 3 Pneumonia
36 F/54 48 Cancer
40 M/37 5 Pneumonia
43 M/56 42 Cancer
56 F/45 36 Cancer
59 M/58 5 Pneumonia
Table 4. Cause of death in 10 patients with adult DM
DM, dermatomyositis; ILD, interstitial lung disease.
Fig. 1. Survival curve of 16 patients with juvenile DM and 48 with
adult DM. Number of available adult DM patients: 42 at 1-yr follow
up, 40 at 3-yr follow up, and 38 at 9-yr follow up. 
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has varied from 6-60% in most large population-based cohort
studies, revealing a frequency of about 20-25%. Malignancy
is more common in older patients (>50 yr) and rare in child-
hood (20, 21). In our study, malignancy was found in 6 out
of 48 patients with adult DM (12.5%) and in none with juve-
nile DM. There have been reports explaining the association
of DM with malignancy. Some authors have postulated that
tumor antigens produce autoantibodies that cross-react with
various components of muscle in a small percentage of pati-
ents (22, 23). Less likely, the tumor releases myotoxic sub-
stances that instigate muscle fiber necrosis and inflammation.
A third possibility is that both the neoplasm and myositis
have a common pathogenesis. 
A wide variety of malignancies have been reported in pa-
tients with DM. Gynecologic malignancy, particularly ovar-
ian carcinoma, may be overrepresented in DM (19, 24). In
our study, gynecologic malignancy such as ovarian cancer and
cervical cancer were found in 3 out of 48 patients with adult
DM. Asians with DM are often found to have nasopharyn-
geal cancer (25). In our study, nasopharyngeal cancer was
found in 2 out of 48 patients with adult DM. 
The inflammatory myopathies in approximately 20% of
patients are associated with connective tissue diseases such
as scleroderma, mixed connective tissue disease, Sjo_gren syn-
drome, systemic lupus erythematosus, and rheumatoid arthri-
tis (10, 11), and is called the ‘‘overlap syndrome’’. In our study,
overlap syndrome was found in 12.5% of juvenile DM patients
and 22.9% of adult DM patients. 
A several studies have evaluated the short- and long-term
outcomes of DM (26-31). We observed that 56.2% of juve-
nile DM patients achieved remission whereas 37.5% improv-
ed and 6.3% worsened in clinical status. In contrast, we ob-
served that 37.5% of adult DM patients achieved remission
whereas 35.4% improved and 27.1% worsened in clinical
status or died. Our findings confirm the results from other
studies showing DM remission rates varying from 25-70%
(32-35). We observed that the outcomes of juvenile DM were
than adult DM.
In previous studies on the survival of DM patients, survival
ranged from 72-84%, 3-73%, and 42-85% at 2, 5, and 10
yr, respectively (2, 26, 32, 34, 36). In our study, we found
that 88%, 83%, and 72% of adult DM patients were still
alive at 1, 3, and 4 yr at follow up, respectively (Fig. 1). The
survival difference between juvenile and adult DM by log-
rank test was statistically not significant (P=0.0544). This
suggests that if more patients were enrolled in the study, a
statistically significant difference may have been seen between
juvenile and adult DM.
Kang et al. (37) have demonstrated that ILD occurs in pa-
tients with adult DM, and in this subset of idiopathic inflam-
matory myopathy, survival of patients is poor. In our study,
5 adult DM patients with ILD died.
DM has further been reported to be associated with incre-
ased mortality with a total mortality rate ranging from 4-
50% (32, 34, 38, 39). Cancer, lung, and cardiovascular com-
plications are generally cited as the most common causes of
death in DM patients (26, 27, 35, 36, 40). In our series, the
mortality rate of juvenile and adult DM patients was 0% and
20.8%. Among the 10 adult DM patients who died, 5 died
within 1 yr of DM diagnosis. The leading cause of death was
cancer in 50% of cases. 
The second leading cause of death in our patients was aspi-
ration pneumonia (33.3% of cases), which occurred during
the first 5 months of adult DM diagnosis. Aspiration pneu-
monia was more often due to DM-related moderate ventila-
tory insufficiency (with decreased cough reflex and inability
to take maximum inspiration) in these patients. 
In conclusion, the clinical characteristics of juvenile DM
reveal higher frequency of neck muscle involvement and sub-
cutaneous calcifications than those of adult DM. The out-
comes of juvenile DM are better than those of adult DM, and
more aggressive therapy for juvenile DM should be advocated.
We suggest that ILD and malignancy are strongly associated
with mortality of DM. Further studies are needed on a pop-
ulation basis to determine whether the adequate treatment
of ILD or malignancy reduces the mortality of DM patients
and why the frequency of ILD and malignancy is higher in
adult DM patients. 
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